Figure 5B

**Figure 5B:**

Data from the CAR-T cell therapy trials for patients with R/R LBCL show encouraging efficacy, with 3 patients achieving and maintaining CR for more than 24 months. However, further studies and long-term follow-up are needed to fully assess the durability of response. **(A)**: Observed peak expansion of CTX101 levels following 1st infusion by dose. **(B)**: Expansion of CTX101 in subjects following 1st and 2nd infusions. **(C)**: Time since first CTX101 infusion (Months) vs ORR per Lugano 2014 criteria. **(D)**: Time since first CTX101 infusion (Months) vs ORR per BICR, modified guidelines. **(E)**: Time since first CTX101 infusion (Months) vs ORR per mCRS. **(F)**: Time since first CTX101 infusion (Months) vs ORR per iCRS. **(G)**: Time since first CTX101 infusion (Months) vs ORR per mIRC. **(H)**: Time since first CTX101 infusion (Months) vs ORR per iIRC. **(I)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(J)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(K)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(L)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(M)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(N)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(O)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(P)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(Q)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(R)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(S)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(T)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(U)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(V)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(W)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(X)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(Y)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(Z)**: Time since first CTX101 infusion (Months) vs ORR per iIP.

**Figure 6:**

Data from the CAR-T cell therapy trials for patients with R/R LBCL show encouraging efficacy, with 3 patients achieving and maintaining CR for more than 24 months. However, further studies and long-term follow-up are needed to fully assess the durability of response. **(A)**: Observed peak expansion of CTX101 levels following 1st infusion by dose. **(B)**: Expansion of CTX101 in subjects following 1st and 2nd infusions. **(C)**: Time since first CTX101 infusion (Months) vs ORR per Lugano 2014 criteria. **(D)**: Time since first CTX101 infusion (Months) vs ORR per BICR, modified guidelines. **(E)**: Time since first CTX101 infusion (Months) vs ORR per mCRS. **(F)**: Time since first CTX101 infusion (Months) vs ORR per iCRS. **(G)**: Time since first CTX101 infusion (Months) vs ORR per mIRC. **(H)**: Time since first CTX101 infusion (Months) vs ORR per iIRC. **(I)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(J)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(K)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(L)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(M)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(N)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(O)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(P)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(Q)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(R)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(S)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(T)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(U)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(V)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(W)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(X)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(Y)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(Z)**: Time since first CTX101 infusion (Months) vs ORR per iIP.

**Figure 7:**

Data from the CAR-T cell therapy trials for patients with R/R LBCL show encouraging efficacy, with 3 patients achieving and maintaining CR for more than 24 months. However, further studies and long-term follow-up are needed to fully assess the durability of response. **(A)**: Observed peak expansion of CTX101 levels following 1st infusion by dose. **(B)**: Expansion of CTX101 in subjects following 1st and 2nd infusions. **(C)**: Time since first CTX101 infusion (Months) vs ORR per Lugano 2014 criteria. **(D)**: Time since first CTX101 infusion (Months) vs ORR per BICR, modified guidelines. **(E)**: Time since first CTX101 infusion (Months) vs ORR per mCRS. **(F)**: Time since first CTX101 infusion (Months) vs ORR per iCRS. **(G)**: Time since first CTX101 infusion (Months) vs ORR per mIRC. **(H)**: Time since first CTX101 infusion (Months) vs ORR per iIRC. **(I)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(J)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(K)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(L)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(M)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(N)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(O)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(P)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(Q)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(R)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(S)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(T)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(U)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(V)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(W)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(X)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(Y)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(Z)**: Time since first CTX101 infusion (Months) vs ORR per iIP.

**Figure 8:**

Data from the CAR-T cell therapy trials for patients with R/R LBCL show encouraging efficacy, with 3 patients achieving and maintaining CR for more than 24 months. However, further studies and long-term follow-up are needed to fully assess the durability of response. **(A)**: Observed peak expansion of CTX101 levels following 1st infusion by dose. **(B)**: Expansion of CTX101 in subjects following 1st and 2nd infusions. **(C)**: Time since first CTX101 infusion (Months) vs ORR per Lugano 2014 criteria. **(D)**: Time since first CTX101 infusion (Months) vs ORR per BICR, modified guidelines. **(E)**: Time since first CTX101 infusion (Months) vs ORR per mCRS. **(F)**: Time since first CTX101 infusion (Months) vs ORR per iCRS. **(G)**: Time since first CTX101 infusion (Months) vs ORR per mIRC. **(H)**: Time since first CTX101 infusion (Months) vs ORR per iIRC. **(I)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(J)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(K)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(L)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(M)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(N)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(O)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(P)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(Q)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(R)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(S)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(T)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(U)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(V)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(W)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(X)**: Time since first CTX101 infusion (Months) vs ORR per iIP. **(Y)**: Time since first CTX101 infusion (Months) vs ORR per mIP. **(Z)**: Time since first CTX101 infusion (Months) vs ORR per iIP.